REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer”) today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), Seer stockholders have voted to re-elect all seven of Seer’s director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – to Seer’s Board of Directors (the “Board”).
Seer issued the following statement:
We thank our stockholders for their support and engagement over the last several months. This outcome reflects confidence in Seer’s highly qualified, purpose-built Board and our directors’ commitment to advancing the best interests of all stockholders. We remain focused on disciplined execution of our strategy that includes expanding utilization of our growing installed base, securing additional population-scale cohort and biobank studies, advancing our innovation pipeline and scaling platform commercialization with continued cost discipline. The business is building momentum, and we remain confident in Seer’s ability to drive value creation over the long-term.
The voting results announced today are considered preliminary until final results are tabulated and certified by the independent inspector of elections. Seer expects to report the final certified voting results for all proposals on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit
www.seer.bio
.
For more information, please email us at
pr@seer.bio
.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s strategy, execution and business momentum. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
investor@seer.bio
View the Zacks #1 Rank List
Seer Stockholders Re-Elect All Seven Director Nominees at 2026 Annual Meeting
Seer, Inc. announced stockholders re-elected all seven director nominees at its 2026 Annual Meeting.
Quiver AI Summary
Seer, Inc. announced the preliminary voting results from its 2026 Annual Meeting, revealing that stockholders have re-elected all seven director nominees to the Board of Directors. The company expressed gratitude to its stockholders for their support, indicating their confidence in the Board's qualifications and commitment to enhancing stockholder interests. Seer emphasized its focus on executing its strategy, which includes expanding its user base, advancing its innovation pipeline, and improving commercial scalability while maintaining cost discipline. The final voting results will be certified by an independent inspector and reported in a Current Report.
Potential Positives
Potential Negatives
FAQ
What were the preliminary voting results for Seer’s Board of Directors?
Seer stockholders voted to re-elect all seven director nominees to the Board of Directors.
Who are the re-elected directors at Seer?
The re-elected directors include Omid Farokhzad, M.D., Meeta Gulyani, Robert Langer, Sc.D., and others.
When will the final voting results be announced?
Final certified voting results will be reported in a Current Report on Form 8-K filed with the SEC.
What is Seer, Inc.'s main area of expertise?
Seer, Inc. specializes in deep, unbiased proteomics, providing advanced insights through its Proteograph® Product Suite.
Are Seer's products intended for diagnostic procedures?
No, Seer’s products are for research use only and are not intended for diagnostic procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEER Insider Trading Activity
$SEER insiders have traded $SEER stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SEER stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SEER Hedge Fund Activity
We have seen 15 institutional investors add shares of $SEER stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer”) today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), Seer stockholders have voted to re-elect all seven of Seer’s director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – to Seer’s Board of Directors (the “Board”).
Seer issued the following statement:
We thank our stockholders for their support and engagement over the last several months. This outcome reflects confidence in Seer’s highly qualified, purpose-built Board and our directors’ commitment to advancing the best interests of all stockholders. We remain focused on disciplined execution of our strategy that includes expanding utilization of our growing installed base, securing additional population-scale cohort and biobank studies, advancing our innovation pipeline and scaling platform commercialization with continued cost discipline. The business is building momentum, and we remain confident in Seer’s ability to drive value creation over the long-term.
The voting results announced today are considered preliminary until final results are tabulated and certified by the independent inspector of elections. Seer expects to report the final certified voting results for all proposals on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio .
For more information, please email us at pr@seer.bio .
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s strategy, execution and business momentum. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
investor@seer.bio
Read full article here »